Navigation Links
Blood Marker Helps Predict Prognosis Among Those With Abdominal Infection

Monitoring blood levels of a compound known as procalcitonin in patients with peritonitis (a serious intra-abdominal infection) could help identify// patients at increased risk of organ failure and death, according to a report.

Organ failure related to blood stream infection (sepsis) is the leading cause of death in surgical intensive care units, accounting for up to 60 percent of deaths, according to background information in the article. Peritonitis, infection of the layer of tissue lining the abdominal wall, is one of the most important sources of abdominal sepsis. Secondary peritonitis occurs as a consequence of another condition, such as a puncture in the gastrointestinal tract that allows the spread of bacteria, and generally this underlying condition must be treated surgically. However, continuing or new-onset abdominal sepsis continues to be a major problem for these patients following surgery, placing them at risk of multi-organ dysfunction syndrome (failure of two or more organ systems) and death.

"Facing this clinical dilemma, there is major interest in the search for an optimum diagnostic tool for an early, noninvasive and reliable diagnosis of abdominal infections and sepsis," the authors write. Currently, these conditions are diagnosed with imaging procedures and guided aspiration (suction) techniques. "An accurate and readily available biochemical marker for identifying patients at risk for abdominal infections would definitely contribute to easier and safer diagnosis."

Bettina M. Rau, M.D., University of the Saarland, Homber/Saar, Germany, and colleagues enrolled 82 patients with secondary peritonitis between 1999 and 2004 in a study to determine whether procalcitonin could be such a marker. Procalcitonin, an inactive precursor to a hormone known as calcitonin, has been shown to be more prevalent in patients with bacterial and fungal infections and sepsis. Bacterial specimens were obtained from the abdomens of all participants, as were other tissue cultures when sepsis was suspected. The patients were monitored from within 96 hours of their first symptoms to a maximum of 21 days for levels of procalcitonin and another marker of inflammation, C-reactive protein, and for signs of lung or kidney failure.

Over the follow-up period, 42 patients developed lung failure, 25 developed kidney failure, 35 had multiorgan dysfunction syndrome (31 cases of which were related to sepsis) and nine died. "Procalcitonin concentrations were most closely correlated with the development of septic multi-organ dysfunction syndrome, with peak levels occurring early after symptom onset or during the immediate post-operative course," the authors write. "No such correlation was observed for C-reactive protein."

It was possible to predict multi-organ dysfunction syndrome by assessing procalcitonin levels on the first two days following surgery; those with values of 10 nanograms per milliliter on two consecutive days were at higher risk. "Persisting procalcitonin levels greater than 1 nanogram per milliliter beyond the first week after disease onset strongly indicated non-survival and were significantly better than C-reactive protein in assessing overall prognosis," they continue.

"In summary, the present prospective, international multi-center study shows that monitoring of procalcitonin levels is a fast and reliable approach to assessing severe septic complications and overall prognosis in patients with secondary peritonitis," the authors conclude. "This single-test marker improves stratification of patients who will develop clinically relevant complications."

Source-Eurekalert
'"/>




Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Blood clots likely in long travel
4. Hemochromatosis Patients Blood is Safe
5. Blood transfusions beneficial after heart attacks
6. Blood Pressure Drug may slow wasting in burn victims
7. Levels Of Blood Proteins May Help Heart Disease Care
8. Blood test may identify ovarian cancer
9. A Blood test for suicide risk?
10. Blood Pressure Drugs maintain muscle strength
11. Blood test diagnoses heart failure in short time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:12/6/2016)... Georgia (PRWEB) , ... December 06, 2016 , ... ... consecutive year to "Training" magazine’s 2017 Training Top 125 for their industry leading ... This prestigious, annual award recognizes USA as among the global elite in employer-sponsored ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, ... today on its R&D program in the use ... pulmonary disease (COPD). In June, 2015 InMed initiated ... to identify the targets and potential active compounds ... COPD. Subsequently, with in vitro assays using human ...
(Date:12/5/2016)... WARSAW, Ind. , Dec. 5, 2016  Zimmer ... "Company") today announced that, pursuant to its previously-announced ... securities identified in the table below (collectively, the ... Notes were validly tendered and not validly withdrawn ... York City time, today, December 5, ...
(Date:12/5/2016)... 5, 2016 Sangamo BioSciences, Inc. (Nasdaq: ... presentation of preclinical and manufacturing data that support SB-525, its ... Annual Meeting of the American Society of Hematology (ASH) ... from December 3-6, 2016. "We have developed an ... we believe is highly competitive, and we remain on track ...
Breaking Medicine Technology: